POS0910 A MULTIPLEX RT-QPCR KIT FOR EXPRESSION ANALYSIS OF INTERFERON-STIMULATED GENES AS A USEFUL TOOL FOR MOLECULAR STRATIFICATION IN LUPUS AND OTHER AUTOIMMUNE DISEASES

It is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases (AIDs) [1], such as systemic erythematosus lupus (SLE), idiopathic inflammatory myopathies (IIM) and rheumatoid arthritis (RA). A quick and ready-to-use m...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 763 - 764
Main Authors Qian, J., Lu, L., Cao, Z., Fu, Q.
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier B.V 01.06.2023
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract It is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases (AIDs) [1], such as systemic erythematosus lupus (SLE), idiopathic inflammatory myopathies (IIM) and rheumatoid arthritis (RA). A quick and ready-to-use method to differentiate IFN activation state is clinically needed. This study aimed to conduct analytical validation of the Multiplex ISGs RT-qPCR Kit in clinical practice We designed a multiplex RT-qPCR method to provide IFN score covering both type I IFN and type II IFN by simultaneously detecting the expression of 3 IFN stimulated genes (ISGs), IFI44, MX1(type I ISGs), and IRF1(type II ISG), relative to one housekeeping gene (HPRT1). Measurements were performed on mRNA extracted from the peripheral blood cells of patients with multiple AIDs. The relative expression of each target gene (T/R) was calculated via 2^-ΔCT. The T/R of each target gene was then normalized as the following: T/R subject - Mean HC/ SD HC. IFN score was calculated as the mean of the normalized T/R of three target genes. Scores higher than the mean of HC plus two SD were designated IFN score high; otherwise, IFN score low. Analytical validation was performed to assess compliance rate, accuracy and method detection limit. Significantly elevated IFN scores were found in SLE(n=116), IIM(n=118), and RA(n=17) compared to other AIDs and HC. Four distinct subpopulations of SLE patients were observed: Thirty-five percent of SLE patients exhibited elevation of all three genes, indicating both type I and type II IFN pathways were activated. 44% of SLE patients had elevated expression of type I ISGs but no change in the type II ISG suggesting only type I IFN pathway was activated. 15% SLE patients presented no elevated expression of ISG gene. And 6% SLE patients only showed increased expression of IRF1 without overexpression of other 2 Type I ISGs, suggesting they probably only had type II IFN pathway activated. We repeated the tests. The compliance rate was 100% and accuracy was 100% with a CV of 0.36%. The method detection limit was 0.61 ng/μL. Using the Multiplex® ISGs RT-qPCR Kit, we assessed the IFN score in multiple AIDs. The analytical validation of the kit reveals that it is a reliable, reproducible diagnostic tool that will be useful in clinical practice but may require confirmation in larger-scale trials. [1]L. Rönnblom, and M.L. Eloranta, The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25 (2013) 248-53. The authors thank the patients for participating in the study. None Declared. [Display omitted]
AbstractList BackgroundIt is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases (AIDs) [1], such as systemic erythematosus lupus (SLE), idiopathic inflammatory myopathies (IIM) and rheumatoid arthritis (RA). A quick and ready-to-use method to differentiate IFN activation state is clinically needed.ObjectivesThis study aimed to conduct analytical validation of the Multiplex ISGs RT-qPCR Kit in clinical practiceMethodsWe designed a multiplex RT-qPCR method to provide IFN score covering both type I IFN and type II IFN by simultaneously detecting the expression of 3 IFN stimulated genes (ISGs), IFI44, MX1(type I ISGs), and IRF1(type II ISG), relative to one housekeeping gene (HPRT1). Measurements were performed on mRNA extracted from the peripheral blood cells of patients with multiple AIDs. The relative expression of each target gene (T/R) was calculated via 2^-ΔCT. The T/R of each target gene was then normalized as the following: T/R subject - Mean HC/ SD HC. IFN score was calculated as the mean of the normalized T/R of three target genes. Scores higher than the mean of HC plus two SD were designated IFN score high; otherwise, IFN score low. Analytical validation was performed to assess compliance rate, accuracy and method detection limit.ResultsSignificantly elevated IFN scores were found in SLE(n=116), IIM(n=118), and RA(n=17) compared to other AIDs and HC. Four distinct subpopulations of SLE patients were observed: Thirty-five percent of SLE patients exhibited elevation of all three genes, indicating both type I and type II IFN pathways were activated. 44% of SLE patients had elevated expression of type I ISGs but no change in the type II ISG suggesting only type I IFN pathway was activated. 15% SLE patients presented no elevated expression of ISG gene. And 6% SLE patients only showed increased expression of IRF1 without overexpression of other 2 Type I ISGs, suggesting they probably only had type II IFN pathway activated. We repeated the tests. The compliance rate was 100% and accuracy was 100% with a CV of 0.36%. The method detection limit was 0.61 ng/μL.ConclusionUsing the Multiplex® ISGs RT-qPCR Kit, we assessed the IFN score in multiple AIDs. The analytical validation of the kit reveals that it is a reliable, reproducible diagnostic tool that will be useful in clinical practice but may require confirmation in larger-scale trials.Reference[1]L. Rönnblom, and M.L. Eloranta, The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25 (2013) 248-53.Figure 1.The IFN score obtained by the Multiplex® ISGs RT-qPCR Kit among various AIDs[Figure omitted. See PDF]AcknowledgementsThe authors thank the patients for participating in the study.Disclosure of InterestsNone Declared.
It is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases (AIDs) [1], such as systemic erythematosus lupus (SLE), idiopathic inflammatory myopathies (IIM) and rheumatoid arthritis (RA). A quick and ready-to-use method to differentiate IFN activation state is clinically needed. This study aimed to conduct analytical validation of the Multiplex ISGs RT-qPCR Kit in clinical practice We designed a multiplex RT-qPCR method to provide IFN score covering both type I IFN and type II IFN by simultaneously detecting the expression of 3 IFN stimulated genes (ISGs), IFI44, MX1(type I ISGs), and IRF1(type II ISG), relative to one housekeeping gene (HPRT1). Measurements were performed on mRNA extracted from the peripheral blood cells of patients with multiple AIDs. The relative expression of each target gene (T/R) was calculated via 2^-ΔCT. The T/R of each target gene was then normalized as the following: T/R subject - Mean HC/ SD HC. IFN score was calculated as the mean of the normalized T/R of three target genes. Scores higher than the mean of HC plus two SD were designated IFN score high; otherwise, IFN score low. Analytical validation was performed to assess compliance rate, accuracy and method detection limit. Significantly elevated IFN scores were found in SLE(n=116), IIM(n=118), and RA(n=17) compared to other AIDs and HC. Four distinct subpopulations of SLE patients were observed: Thirty-five percent of SLE patients exhibited elevation of all three genes, indicating both type I and type II IFN pathways were activated. 44% of SLE patients had elevated expression of type I ISGs but no change in the type II ISG suggesting only type I IFN pathway was activated. 15% SLE patients presented no elevated expression of ISG gene. And 6% SLE patients only showed increased expression of IRF1 without overexpression of other 2 Type I ISGs, suggesting they probably only had type II IFN pathway activated. We repeated the tests. The compliance rate was 100% and accuracy was 100% with a CV of 0.36%. The method detection limit was 0.61 ng/μL. Using the Multiplex® ISGs RT-qPCR Kit, we assessed the IFN score in multiple AIDs. The analytical validation of the kit reveals that it is a reliable, reproducible diagnostic tool that will be useful in clinical practice but may require confirmation in larger-scale trials. [1]L. Rönnblom, and M.L. Eloranta, The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25 (2013) 248-53. The authors thank the patients for participating in the study. None Declared. [Display omitted]
Author Fu, Q.
Cao, Z.
Lu, L.
Qian, J.
Author_xml – sequence: 1
  givenname: J.
  surname: Qian
  fullname: Qian, J.
  organization: Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Rheumatology, Shanghai, China
– sequence: 2
  givenname: L.
  surname: Lu
  fullname: Lu, L.
  organization: Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Rheumatology, Shanghai, China
– sequence: 3
  givenname: Z.
  surname: Cao
  fullname: Cao, Z.
  organization: Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Institute of Molecular Medicine, Shanghai, China
– sequence: 4
  givenname: Q.
  surname: Fu
  fullname: Fu, Q.
  organization: Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Rheumatology, Shanghai, China
BookMark eNpNkcFq3DAQhkVIoZs07yDI2alkyZJ1NLtyIqq1HEuG9CR2bZk4pN7WzubcSx-nL9UnqTbpoTDMMMM__wx8F-B8OkwBgGuMbjAm7PNumubHcPzWj0uSopQk4fi8m28yzsQZWGHK8jhm6BysEEIkoYLxj-BiWZ5ii3Kcr8Dv2lgkMPrz81cBt612qtbyATYuua_XDfyiHCxNA-VD3UhrlalgURX6q1UWmhKqysmmlI2pEutUXC-c3MBbWUkLixiwtbJsNXTG6DefrdFyHWUNtK4pnCrVOuboqiqo27qNO9UGGncnG1i0zqjttq0k3CgrCyvtJ_Bh2D0v4epfvQRtKd36LtHmNjrpJGBKRNKjQPM9J0TQPg_ZkLGMCD6IMKQdpQgHlJPA8F50jO_TtKec7QdOKM9pz3nIyCW4fvf9Ph9-HMPy4p8Ox3mKJ32aZ4QKwpiIKvmuCvGV1zHMfunGMHWhH-fQvfj-MHqM_ImU_4-UP5Hyb6T8iRT5C5lhguE
ContentType Journal Article
Copyright 2023 © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc.
2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml – notice: 2023 © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc.
– notice: 2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
DBID K9.
DOI 10.1136/annrheumdis-2023-eular.5769
DatabaseName ProQuest Health & Medical Complete (Alumni)
DatabaseTitle ProQuest Health & Medical Complete (Alumni)
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 764
ExternalDocumentID S0003496724644821
GroupedDBID ---
.55
.GJ
.VT
0R~
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AALRI
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
K9.
PHGZM
PJZUB
PPXIY
PQGLB
ID FETCH-LOGICAL-e1439-d0e48b73394d8e5f565397f9ef2c4401e083e61b9c67b22d476bf734784d77e53
ISSN 0003-4967
IngestDate Fri Jul 25 10:55:45 EDT 2025
Sat Mar 15 15:43:59 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Suppl 1
Keywords Validation
Diagnostic tests
Systemic lupus erythematosus
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-e1439-d0e48b73394d8e5f565397f9ef2c4401e083e61b9c67b22d476bf734784d77e53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://ard.bmj.com/content/annrheumdis/82/Suppl_1/763.3.full.pdf
PQID 2853493669
PQPubID 2041045
PageCount 2
ParticipantIDs proquest_journals_2853493669
elsevier_sciencedirect_doi_10_1136_annrheumdis_2023_eular_5769
PublicationCentury 2000
PublicationDate June 2023
20230601
PublicationDateYYYYMMDD 2023-06-01
PublicationDate_xml – month: 06
  year: 2023
  text: June 2023
PublicationDecade 2020
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
PublicationTitle Annals of the rheumatic diseases
PublicationYear 2023
Publisher Elsevier B.V
Elsevier Limited
Publisher_xml – name: Elsevier B.V
– name: Elsevier Limited
SSID ssj0000818
Score 2.4168553
Snippet It is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases (AIDs) [1],...
BackgroundIt is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases...
SourceID proquest
elsevier
SourceType Aggregation Database
Publisher
StartPage 763
SubjectTerms Autoimmune diseases
Blood cells
Clinical medicine
Clinical trials
Diagnostic tests
Genes
Inflammation
Interferon
Interferon regulatory factor 1
Lupus
mRNA
Myxovirus resistance proteins
Peripheral blood
Rheumatoid arthritis
Systemic lupus erythematosus
Validation
Title POS0910 A MULTIPLEX RT-QPCR KIT FOR EXPRESSION ANALYSIS OF INTERFERON-STIMULATED GENES AS A USEFUL TOOL FOR MOLECULAR STRATIFICATION IN LUPUS AND OTHER AUTOIMMUNE DISEASES
URI https://dx.doi.org/10.1136/annrheumdis-2023-eular.5769
https://www.proquest.com/docview/2853493669
Volume 82
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3djpNAFJ7U3WTjjfE3rq6bSfRuQm1hYODGBFtIcWlLCyT1iuzAEL3pJqa98cobH8cn8S18Es8MQ2ndZqMmhBRKDx3Ox5lvZs4PQm-GtW3ZgjmGK1hpQA_tGdcWLw2nhL4BCD6zKuUgO3MmOf2wsle93s89r6XthvfLr0fjSv5Hq3AO9CqjZP9BszuhcAI-g35hDxqG_V_pOJmnsiPWDguu7ZNpHmdREgcrssyMRTJakqsoIzDSI8FKPWxZY8ef-fHHNFJVy1VK3DBYSsuaRfBzH0wZkQ5tKfFhI3kahHlMMlmUQ8qZzuNgBJctiSy3nEWhDkUGSSTOkzxVCavm2SRYEnhM82g6zWcBGUdp4Keaet5K3qz8HD-JbZM_Vi8a7dj-4nMzS7ub0o5JvO0WT24OFlgWJNzuT2WYVudy1cyvtTE2t2O7pAcd9ZrCHX3RmGoZM2YOmmoErS13zT3MqrqoZLhnnltjKvQRPd6JWDp7smo4tNlQf1ZIv-A-jM-8ru9s_QUmflok47CIo9nVPXRqwphFltNgK9bRAnfotuUbZVPO0Gt9s7d33OqAI_3BFhQFyh6iB3rsgv0GiI9QT6wfo7Op9s54gn5oPP769t3HOyRijUQMSMSAINwhEbdIxPMQH0UiVkjEPmy4QSKWSFRydkjEh0gESVghEcSPsUIi7pCIWyQ-RXkYZKOJocuBGAJIvWdUA0FdzizLo5Ur7NqWWZVZ7YnaLCkdDAWMJoQz5F7pMG6aFWUOr5lFmUsrxoRtPUMn65u1eI4wHJVeyTkfVANaAQnnVkXt69q15XQH987Ru_apF5qJNgyzAIwUatxsqVj-Vm2FVFuh1FZItZ2ji1ZXhTYYcA2YP-pZjuO9uPvrl-h-93pcoJPNl614Bdx3wy8Vpi7R6ftglix_A0O9mpQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=POS0910%E2%80%85A+MULTIPLEX+RT-QPCR+KIT+FOR+EXPRESSION+ANALYSIS+OF+INTERFERON-STIMULATED+GENES+AS+A+USEFUL+TOOL+FOR+MOLECULAR+STRATIFICATION+IN+LUPUS+AND+OTHER+AUTOIMMUNE+DISEASES&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Qian%2C+J&rft.au=L+Lu&rft.au=Cao%2C+Z&rft.au=Q+Fu&rft.date=2023-06-01&rft.pub=Elsevier+Limited&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=82&rft.issue=Suppl+1&rft.spage=763&rft.epage=764&rft_id=info:doi/10.1136%2Fannrheumdis-2023-eular.5769&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon